Serpin Pharma has entered a strategic partnership with Dogwood Therapeutics to develop and commercialize SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced peripheral neuropathy (CIPN). SP16 IV, the intravenous formulation, has shown dual anti-inflammatory and neural repair effects in preclinical studies and will enter a Phase 1b trial in early 2026, fully funded by the National Cancer Institute.
Dogwood, led by former Pfizer executive Greg Duncan, brings deep expertise in pain and inflammation drug development, having helped launch ten approved therapies. Duncan noted the partnership aligns with Dogwood’s focus on non-opioid pain solutions and enhances shareholder value without immediate capital investment.
SP16 mimics the activity of alpha-1-antitrypsin (A1AT), offering both symptom relief and nerve repair. It may also complement Dogwood’s lead candidate, Halneuron®, in addressing non-pain symptoms of CIPN.
This collaboration underscores Serpin’s commitment to immunoregulatory innovation and precision medicine.